HLA-DPB1 glutamate 69: a genetic marker of beryllium disease
HLA-DPB1 glutamate 69: a genetic marker of beryllium disease
Chronic beryllium disease (CBD) is a lung disorder related to beryllium exposure and is characterized by the accumulation in the lung of beryllium-specific CD4+ major histocompatibility complex (MHC) class II-restricted T lymphocytes. Evaluation of MHC class II genes in 33 CBD cases and 44 controls has shown a negative association with HLA-DPB1*0401 (P < 0.001) and a positive association with HLA-DPB1*0201 (P < 0.05) alleles, which differ at residues 36, 55 to 56, and 69 of the beta 1 chain. Among CBD cases, 97 percent expressed the HLA-DPB1*0201-associated glutamic acid (unaffected population, 30 percent; P < 0.001) at residue 69, a position involved in susceptibility to autoimmune disorders. This suggests that HLA-DP has a role in conferring susceptibility and that residue 69 of HLA-DPB1 could be used in risk assessment for CBD.
242-244
Richeldi, L.
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Sorrentino, R.
b6c52d74-0e96-45fa-8f02-5c3fcd2f3f11
Saltini, C.
511217a8-2901-4ca3-bbdf-b54611e4acc2
8 October 1993
Richeldi, L.
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Sorrentino, R.
b6c52d74-0e96-45fa-8f02-5c3fcd2f3f11
Saltini, C.
511217a8-2901-4ca3-bbdf-b54611e4acc2
Abstract
Chronic beryllium disease (CBD) is a lung disorder related to beryllium exposure and is characterized by the accumulation in the lung of beryllium-specific CD4+ major histocompatibility complex (MHC) class II-restricted T lymphocytes. Evaluation of MHC class II genes in 33 CBD cases and 44 controls has shown a negative association with HLA-DPB1*0401 (P < 0.001) and a positive association with HLA-DPB1*0201 (P < 0.05) alleles, which differ at residues 36, 55 to 56, and 69 of the beta 1 chain. Among CBD cases, 97 percent expressed the HLA-DPB1*0201-associated glutamic acid (unaffected population, 30 percent; P < 0.001) at residue 69, a position involved in susceptibility to autoimmune disorders. This suggests that HLA-DP has a role in conferring susceptibility and that residue 69 of HLA-DPB1 could be used in risk assessment for CBD.
This record has no associated files available for download.
More information
Published date: 8 October 1993
Organisations:
Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 368933
URI: http://eprints.soton.ac.uk/id/eprint/368933
ISSN: 0036-8075
PURE UUID: 2abb0e60-7b96-45df-b747-d7c1ca200b65
Catalogue record
Date deposited: 23 Sep 2014 11:21
Last modified: 14 Mar 2024 17:56
Export record
Altmetrics
Contributors
Author:
L. Richeldi
Author:
R. Sorrentino
Author:
C. Saltini
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics